RU2019143573A - Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar - Google Patents
Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar Download PDFInfo
- Publication number
- RU2019143573A RU2019143573A RU2019143573A RU2019143573A RU2019143573A RU 2019143573 A RU2019143573 A RU 2019143573A RU 2019143573 A RU2019143573 A RU 2019143573A RU 2019143573 A RU2019143573 A RU 2019143573A RU 2019143573 A RU2019143573 A RU 2019143573A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- disorder
- cycloserine
- depression
- agent
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title claims 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title claims 4
- 239000005557 antagonist Substances 0.000 title claims 3
- 238000002648 combination therapy Methods 0.000 title 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical group N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 8
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- -1 vilazadone Chemical compound 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 2
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 claims 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims 2
- 229960003299 ketamine Drugs 0.000 claims 2
- 229960000685 levomilnacipran Drugs 0.000 claims 2
- 229960000600 milnacipran Drugs 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- ABAPCYNTEPGBNJ-FTGAXOIBSA-N tert-butyl (4S)-2-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-3-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate Chemical compound NC([C@H]([C@@H](C)O)N1C([C@]2(C1)N(CCC2)C(=O)OC(C)(C)C)=O)=O ABAPCYNTEPGBNJ-FTGAXOIBSA-N 0.000 claims 2
- 229960002263 vortioxetine Drugs 0.000 claims 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 2
- NFXPEHLDVKVVKA-ISTVAULSSA-N (2S,3R)-3-hydroxy-2-[(4R)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide Chemical compound C[C@@H](O)[C@H](N1C[C@]2(CCCN2C(=O)C(C)C)C1=O)C(N)=O NFXPEHLDVKVVKA-ISTVAULSSA-N 0.000 claims 1
- DVBUEXCIEIAXPM-PJUQSVSOSA-N (2r)-1-[(2s)-1-[(2s,3r)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-2-benzylpyrrolidine-2-carboxamide Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@@](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)(CC=2C=CC=CC=2)CCC1 DVBUEXCIEIAXPM-PJUQSVSOSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010042458 Suicidal ideation Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Claims (17)
1. Композиция для применения для лечения нейропсихиатрического расстройства, связанного с рецептором NMDA, у субъекта-человека, нуждающегося в этом, содержащая терапевтически эффективное количество: первого агента, состоящего из антагониста рецептора NMDA; и второго агента, состоящего из антидепрессанта, выбранного из группы, состоящей из левомилнаципрана, милнаципрана, вилазадона, вортиоксетина, S-миртазапина и R-миртазапина, и при этом нейропсихиатрическое расстройство, связанное с рецептором NMDA, выбрано из группы, состоящей из депрессии, обсессивно-компульсивного расстройства и тревожных расстройств.
2. Композиция по п. 1, отличающаяся тем, что первый агент представляет собой D-циклосерин, представленный в дозе, при которой D-циклосерин действует как фактический антагонист.
3. Композиция по п. 2, отличающаяся тем, что D-циклосерин вводят в дозе от ≥500 мг/сутки до ≤1000 мг/сутки, и он составлен так, чтобы обеспечивать среднее содержание в плазме субъекта более 25 мкг/мл.
4. Композиция по п. 2 или 3, отличающаяся тем, что D-циклосерин вводят в дозе 7,5-12,5 мг/кг/сутки.
5. Композиция по п. 1, отличающаяся тем, что первый агент выбран из группы, состоящей из кетамина, GlyX-13, NRX-1074, NYX-2925, AGN-241751 и гавестинела.
6. Композиция по п. 1, отличающаяся тем, что нейропсихиатрическое расстройство, связанное с рецептором NMDA, представляет собой депрессию.
7. Композиция по п. 6, отличающаяся тем, что депрессия представляет собой большую депрессию, большое депрессивное расстройство, атипичную, ажитированную, меланхолическую депрессию или дистимическое расстройство.
8. Композиция по п. 1, отличающаяся тем, что депрессия представляет собой биполярное расстройство.
9. Композиция по п. 8, отличающаяся тем, что биполярное расстройство представляет собой депрессивное расстройство биполярного типа I или биполярного типа 2.
10. Композиция по п. 8, отличающаяся тем, что биполярное расстройство связано с депрессивными или смешанными эпизодами, связанными с биполярной депрессией.
11. Композиция по любому из пп. 1-10, уменьшающая симптомы депрессии, снижающая частоту суицидов или обеспечивающая лечение суицидального мышления у субъекта.
12. Композиция по любому из пп. 1-10, отличающаяся тем, что указанное расстройство связано с суицидальностью.
13. Композиция, содержащая: первый агент, состоящий из антагониста рецептора NMDA; и второй агент, состоящий из антидепрессанта, выбранного из группы, состоящей из левомилнаципрана, милнаципрана, вилазадона, вортиоксетина, S-миртазапина и R-миртазапина.
14. Композиция по п. 13, отличающаяся тем, что первый агент представляет собой D-циклосерин, представленный в дозе, при которой D-циклосерин действует как фактический антагонист.
15. Композиция по п. 14, отличающаяся тем, что D-циклосерин составлен так, чтобы обеспечивать дозу от ≥500 мг/сутки до ≤1000 мг/сутки, и так, чтобы обеспечивать среднее содержание в плазме субъекта более 25 мкг/мл.
16. Композиция по п. 14 или 15, отличающаяся тем, что D-циклосерин составлен так, чтобы обеспечивать дозу 7,5-12,5 мг/кг/сутки.
17. Композиция по п. 13, отличающаяся тем, что первый агент выбран из группы, состоящей из кетамина, GlyX-13, AGN-241751 и гавестинела.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510801P | 2017-05-25 | 2017-05-25 | |
| US62/510,801 | 2017-05-25 | ||
| US201762518020P | 2017-06-12 | 2017-06-12 | |
| US62/518,020 | 2017-06-12 | ||
| PCT/IL2018/050570 WO2018216020A1 (en) | 2017-05-25 | 2018-05-24 | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019143573A true RU2019143573A (ru) | 2021-06-28 |
| RU2019143573A3 RU2019143573A3 (ru) | 2021-09-03 |
Family
ID=64396350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019143573A RU2019143573A (ru) | 2017-05-25 | 2018-05-24 | Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar |
| RU2019143572A RU2019143572A (ru) | 2017-05-25 | 2018-05-24 | Композиции для лечения посттравматического стрессового расстройства |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019143572A RU2019143572A (ru) | 2017-05-25 | 2018-05-24 | Композиции для лечения посттравматического стрессового расстройства |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20180338956A1 (ru) |
| EP (2) | EP3630103A4 (ru) |
| JP (4) | JP7312116B2 (ru) |
| KR (2) | KR102654569B1 (ru) |
| CN (2) | CN110996946A (ru) |
| AU (2) | AU2018274765A1 (ru) |
| BR (2) | BR112019024802A2 (ru) |
| CA (2) | CA3065003A1 (ru) |
| IL (2) | IL270885B1 (ru) |
| MX (2) | MX2019014114A (ru) |
| RU (2) | RU2019143573A (ru) |
| WO (2) | WO2018216020A1 (ru) |
| ZA (2) | ZA201908616B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11426367B2 (en) | 2018-05-04 | 2022-08-30 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020092496A1 (en) * | 2018-10-31 | 2020-05-07 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| EP3952856A4 (en) * | 2019-04-09 | 2023-01-11 | Vistagen Therapeutics, Inc. | GENE VARIANTS ASSOCIATED WITH RESPONSE TO THE TREATMENT OF NEUROLOGICAL DISORDERS |
| MX2022007768A (es) * | 2020-01-03 | 2022-09-27 | Univ Of Padova | Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas. |
| CN115677519A (zh) * | 2021-07-22 | 2023-02-03 | 立科时代(武汉)生物科技有限公司 | L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用 |
| CN113648320A (zh) * | 2021-08-16 | 2021-11-16 | 中国人民解放军军事科学院军事医学研究院 | 赛洛西宾抗创伤后应激障碍的医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| DE1073432T1 (de) * | 1998-04-14 | 2002-02-07 | Gen Hospital Corp | Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden |
| WO2005016319A2 (en) | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US7601740B2 (en) | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| WO2005079756A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| SG161221A1 (en) | 2004-09-27 | 2010-05-27 | Acadia Pharm Inc | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| TW200631584A (en) * | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
| EP2099444A4 (en) | 2006-12-14 | 2012-11-07 | Nps Pharma Inc | USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| ES2673956T3 (es) | 2011-01-31 | 2018-06-26 | Serotech, Llc | Régimen de dosificación, envase de dispensación de la medicación y usos de los mismos para el tratamiento del trastorno depresivo mayor |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2841063A2 (en) | 2012-04-27 | 2015-03-04 | Indiana University Research and Technology Corporation | Compositions and methods for treating ptsd and related diseases |
| MX370612B (es) * | 2013-10-18 | 2019-12-18 | Psyadon Pharmaceuticals Inc | Benzazepinas fusionadas para el tratamiento de la tartamudez. |
| EP3197440A4 (en) | 2014-09-22 | 2018-04-18 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016061320A2 (en) | 2014-10-15 | 2016-04-21 | Rowan University | Timber therapy for post-traumatic stress disorder |
| SG10201914045QA (en) | 2015-08-04 | 2020-03-30 | Confluence Pharmaceuticals Llc | Combination therapy using acamprosate and d-cycloserine |
-
2018
- 2018-05-24 CA CA3065003A patent/CA3065003A1/en active Pending
- 2018-05-24 WO PCT/IL2018/050570 patent/WO2018216020A1/en active Application Filing
- 2018-05-24 CN CN201880048442.XA patent/CN110996946A/zh active Pending
- 2018-05-24 RU RU2019143573A patent/RU2019143573A/ru not_active Application Discontinuation
- 2018-05-24 BR BR112019024802-1A patent/BR112019024802A2/pt unknown
- 2018-05-24 KR KR1020197038205A patent/KR102654569B1/ko active IP Right Grant
- 2018-05-24 EP EP18806042.0A patent/EP3630103A4/en active Pending
- 2018-05-24 IL IL270885A patent/IL270885B1/en unknown
- 2018-05-24 EP EP18805411.8A patent/EP3630102A4/en active Pending
- 2018-05-24 AU AU2018274765A patent/AU2018274765A1/en active Pending
- 2018-05-24 JP JP2019564988A patent/JP7312116B2/ja active Active
- 2018-05-24 WO PCT/IL2018/050567 patent/WO2018216018A1/en active Application Filing
- 2018-05-24 CN CN201880048653.3A patent/CN110996947A/zh active Pending
- 2018-05-24 BR BR112019024817-0A patent/BR112019024817A2/pt active Search and Examination
- 2018-05-24 US US15/987,941 patent/US20180338956A1/en not_active Abandoned
- 2018-05-24 MX MX2019014114A patent/MX2019014114A/es unknown
- 2018-05-24 MX MX2019014113A patent/MX2019014113A/es unknown
- 2018-05-24 KR KR1020197038209A patent/KR102608479B1/ko active IP Right Grant
- 2018-05-24 AU AU2018274767A patent/AU2018274767A1/en active Pending
- 2018-05-24 RU RU2019143572A patent/RU2019143572A/ru not_active Application Discontinuation
- 2018-05-24 US US15/987,933 patent/US10881665B2/en active Active
- 2018-05-24 CA CA3064846A patent/CA3064846A1/en active Pending
- 2018-05-24 JP JP2019564867A patent/JP7308761B2/ja active Active
-
2019
- 2019-11-25 IL IL270916A patent/IL270916A/en unknown
- 2019-12-23 ZA ZA2019/08616A patent/ZA201908616B/en unknown
- 2019-12-23 ZA ZA2019/08617A patent/ZA201908617B/en unknown
-
2022
- 2022-01-28 US US17/586,828 patent/US20220143041A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034164A patent/JP2023071900A/ja active Pending
- 2023-05-10 JP JP2023077666A patent/JP2023100904A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019143573A (ru) | Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar | |
| EA200970706A1 (ru) | Новые фармацевтические композиции | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| JP2023071900A5 (ru) | ||
| MY153027A (en) | Combined preparation for the treatment of cardiovascular diseases based on chronotheraphy theory | |
| WO2007078895A3 (en) | Modified release formulations of tramadol and uses thereof | |
| TW200630105A (en) | Herbal composition PHY906 and its use in chemotherapy | |
| MX2010009447A (es) | Uso de antagonistas de lhrh a dosis no castrantes. | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| NZ739392A (en) | Methods for treating hepcidin-mediated disorders | |
| EP3276004A3 (en) | Methods for treating chronic kidney disease | |
| MX2021013427A (es) | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. | |
| MXPA05011858A (es) | Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico. | |
| PH12020551726A1 (en) | Treatment of atopic dermatitis | |
| MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
| MX2021002322A (es) | Nuevos metodos. | |
| EP3309555A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| MX2021005839A (es) | Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso. | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| EA201892583A1 (ru) | Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220418 |